There was an outcry from insulin users when Novo Nordisk and Eli Lilly decided to withdraw animal-derived basal insulins from the market and replace them with biosynthetic NPH and Ultralente, which many consumers consider inferior. These same critics are hoping that a new generation of basal insulins such as HOE901, Basulin and Lantus will prove to be more effective.
In a multinational study, the effect of HOE901 on the blood glucose control of 333 type 1 patients was compared to that of NPH insulin over a period of four weeks. It was found that both fasting plasma and self-monitored blood glucose levels were much lower with HOE901. HbA1c levels and the frequency of nighttime lows were also significantly lower with HOE901 versus NPH.